Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project.

Gianluca SpiteriMarika D'AgostiniMahsa AbediniGiorgia DitanoGiulia CollatuzzoPaolo BoffettaLuigi VimercatiEmanuele SansoneGiuseppe De PalmaAlberto ModeneseFabriziomaria GobbaFilippo LivieroAngelo MorettoMarco dell'OmoTiziana FiordiFrancesca Larese FilonMarcella MauroConcepción ViolánDana MatesJana Oravec BérešováMaria Grazia Lourdes MonacoAngela CartaGiuseppe VerlatoStefano Porru

Published in: Infection (2024)

Vaccine effectiveness wanes significantly after new variants surge, making anti-S titer unsuitable to predict optimal timing for further booster dose administration. Studies on other immunological indicators, such as cellular immunity, are therefore needed to better understand the mechanisms and duration of protection against breakthrough infection risk.

Keyphrases

sars cov
randomized controlled trial
quality improvement
respiratory syndrome coronavirus
gene expression
dna methylation
case control
coronavirus disease